Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Stroke is one of the three leading causes of human death, and a major cause of adult disability. Our pre-clinical studies confirmed that ischemic preconditioning can prevent cerebral infarction. Animal studies confirmed that ischemic postconditioning can reduce infarct size of cerebral infarction. Investigators hypothesized that postconditioning would reduce infarct volume of ischemic stroke patients.
This study explored the neuroprotective effects of post-positioning on ischemic stroke patients with randomized, double-blinded and controlled method. Patients are divided into experimental and placebo groups to receive remote ischemic post-conditioning for 30 days. Remote ischemic post-conditioning is performed by the inflating tourniquets to certain extents on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days. It is 200mmHg for RIPC group and 60mmHg for control group. Evaluation parameters include CRP, TNF-α, ICAM-1 and GFAP in blood at 0, 3, 7, 15 and 30 days after treatment; and MRI at 0 and 30 days after treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RIPC group | Experimental | RIPC treatment was performed by the inflating tourniquets to 200mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days. |
|
| Control group | Sham Comparator | RIPC sham was performed by the inflating tourniquets to 60mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RIPC group | Device |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Local tissue damage 30 days after RIPC treatment | Evaluated by the doctor blinded to the study protocol, including: local edema, redness, skin breakage | 30 days after RIPC treatment |
| Levels of plasma biomarkers assay right before RIPC treatment | levels of CRP、TINF-α、slCAM-1 and GFAP | right before RIPC treatment (within 24hrs) |
| Levels of plasma biomarkers assay 3 days after RIPC treatment. | levels of CRP、TINF-α、slCAM-1 and GFAP | 3 days after RIPC treatment. |
| Levels of plasma biomarkers assay 15 days after RIPC treatment. | levels of CRP、TINF-α、slCAM-1 and GFAP | 15 days after RIPC treatment. |
| Levels of plasma biomarkers assay 30 days after RIPC treatment | levels of CRP、TINF-α、slCAM-1 and GFAP | 30 days after RIPC treatment |
| Levels of plasma biomarkers assay right after RIPC treatment | levels of CRP、TINF-α、slCAM-1 and GFAP | right after RIPC treatment (within 24hrs) |
| Measure | Description | Time Frame |
|---|---|---|
| Infarct volume evaluation before RIPC treatment. | MRI evaluation of infarct volume in ischemic stroke patients before RIPC treatment. | Acute phase of ischemic stroke, and before RIPC treatment |
| Infarct volume after RIPC treatment in ischemic stroke patients |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020521 | Stroke |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Control group | Device |
|
|
Infarct volume evaluation in ischemic stroke patients after 30 RIPC treatment |
| 30 days after RIPC treatment in ischemic stroke patients |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D008722 | Methods |